Pelthos Therapeutics (PTHS) Investment Analysis: ZELSUVMI™ Commercialization in Full Swing—Tug-of-War Between the NO Platform and Single-Product Risk
Pelthos Therapeutics (PTHS) Investment Analysis: ZELSUVMI™ Commercialization in Full Swing—Tug-of-War Between the NO Platform and Single-Product Risk※ Pelthos Therapeutics (NYSE American: PTHS) is a dermatology biotech that launched ZELSUVMI™ (berdazimer 10.3%) in the U.S. in July 2025 for molluscum contagiosum. With the merger with Channel Therapeutics and a $50.1M private placement, the compan..
In-Depth Analysis of USAS (Americas Silver) Stock: Price Drivers, Technical Trends, Future Value, and Investment Strategies
In-Depth Analysis of USAS (Americas Silver) Stock: Price Drivers, Technical Trends, Future Value, and Investment Strategies※ Americas Silver Corporation (NYSEAMERICAN: USAS) is a leading small- to mid-cap mining company operating and developing major silver, zinc, and lead mines across North America. The company’s stock reflects both unique risks and growth potential, driven by recent volatility..